Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo.
David RosmarinThierry PasseronAmit G PandyaPearl GrimesJohn E HarrisSeemal R DesaiMark LebwohlMireille Ruer-MulardJulien SeneschalAlbert WolkerstorferDeanna KornackiKang SunKathleen ButlerKhaled Ezzedinenull nullPublished in: The New England journal of medicine (2022)
In two phase 3 trials, application of ruxolitinib cream resulted in greater repigmentation of vitiligo lesions than vehicle control through 52 weeks, but it was associated with acne and pruritus at the application site. Larger and longer trials are required to determine the effect and safety of ruxolitinib cream in patients with vitiligo. (Funded by Incyte; TRuE-V1 and TRuE-V2 ClinicalTrials.gov numbers, NCT04052425 and NCT04057573.).